Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR(+) non-small-cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as erlotinib, are standard-of-care for patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC), but most patients progress within 1 year. Previously, we demonstrated that erlotinib plus bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Atagi, Shinji, Goto, Koichi, Hosomi, Yukio, Seto, Takashi, Hida, Toyoaki, Nakagawa, Kazuhiko, Yoshioka, Hiroshige, Nogami, Naoyuki, Maemondo, Makoto, Nagase, Seisuke, Okamoto, Isamu, Yamamoto, Noboru, Igawa, Yuriko, Tajima, Kosei, Fukuoka, Masahiro, Yamamoto, Nobuyuki, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326775/
https://www.ncbi.nlm.nih.gov/pubmed/37425411
http://dx.doi.org/10.21037/tlcr-22-632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326775/
https://www.ncbi.nlm.nih.gov/pubmed/37425411
http://dx.doi.org/10.21037/tlcr-22-632

Ejemplares similares